Dexmedetomidine in Seizure Patients
The Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Patients With Seizure Disorders
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94122
- University of California San Francisco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65, BMI 20-25 kg/m2
- Anticonvulsant Group: Diagnosis of seizure disorder taking carbamazepine or phenytoin for a minimum of 2 weeks
- Control Group: Healthy volunteers taking no medications
Exclusion Criteria:
- Positive urine pregnancy test or lactating
- History of allergy to dexmedetomidine or alpha -2 agonists
- History of liver, renal or thyroid disease
- History of cardiovascular disease including history of arrhythmia or congestive heart failure
- History of drug or alcohol abuse
Study Plan
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum level of dexmedetomidine
Time Frame: 0-8 hour period
|
Serum levels of dexmedetomidine will be taken at specific intervals during and after a step-wise computer controlled infusion of dexmedetomidine.
|
0-8 hour period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient State Index (PSI) and Entropy
Time Frame: 0-8h
|
PSI and/or state entropy will be recorded at specific intervals during and after a step-wise computer controlled infusion of dexmedetomidine.
|
0-8h
|
|
Visual Analog Scale score
Time Frame: 0-8h
|
VAS scores will be recorded at specific intervals during and after a step-wise computer controlled infusion of dexmedetomidine.
|
0-8h
|
|
Ramsay Sedation Score
Time Frame: 0-8h
|
Ramsay sedation scores will be recorded at specific intervals during and after a step-wise computer controlled infusion of dexmedetomidine.
|
0-8h
|
|
Observer's Assessment of Alertness/Sedation Score (OAA/S)
Time Frame: 0-8h
|
OAA/S scores will be recorded at specific intervals during and after a step-wise computer controlled infusion of dexmedetomidine.
|
0-8h
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alana M Flexman, MD, UCSF Department of Anesthesia
- Principal Investigator: Pekka Talke, MD, UCSF Department of Anesthesia
- Principal Investigator: Paul Garcia, MD, UCSF Department of Neurology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Epilepsy
- Seizures
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
Other Study ID Numbers
- UCSF-AF-02-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.